Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Company Overview

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies.

Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment.

Key Stats

• Today's Range: $41.49 to $42.33
• 50-Day Range: $27.25 to $48.11
• 52-Week Range: $14.78 to $48.53
• Volume: 48,740 shs
• Average Volume: 1.20 million shs
• Market Capitalization: $2.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.40
• Consensus Rating: Moderate Buy

Enliven Therapeutics Stock Analysis - MarketRank™

Enliven Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 606th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enliven Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Enliven Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Enliven Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Enliven Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enliven Therapeutics is -22.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enliven Therapeutics is -22.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enliven Therapeutics has a P/B Ratio of 5.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.91% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 4.28.

Change versus previous month

Short interest in Enliven Therapeutics has recently decreased by 11.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enliven Therapeutics does not currently pay a dividend.

Dividend Growth

Enliven Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.81

News Sentiment

Enliven Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Enliven Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $473,201.00 in company stock.

Percentage Held by Insiders

25.90% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELVN Stock Analysis - Frequently Asked Questions

How have ELVN shares performed this year?

Enliven Therapeutics' stock was trading at $15.40 at the start of the year. Since then, ELVN stock has increased by 170.0% and is now trading at $41.58.

How were Enliven Therapeutics' earnings last quarter?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its quarterly earnings data on Tuesday, March, 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06.

When did Enliven Therapeutics IPO?

Enliven Therapeutics (ELVN) raised $80 million in an initial public offering (IPO) on Thursday, March 12th 2020. The company issued 4,700,000 shares at $16.00-$18.00 per share.

Who are Enliven Therapeutics' major shareholders?

Enliven Therapeutics' top institutional investors include Pictet Asset Management Holding SA (1.53%), Candriam S.C.A. (0.98%), Capricorn Fund Managers Ltd (0.61%) and Bank of New York Mellon Corp (0.20%). Insiders that own company stock include Samuel Kintz, 5Am Partners Vi, Llc, Joseph P Lyssikatos, Rishi Gupta, Anish Patel, Benjamin Hohl, Richard A Heyman and Rahul D Ballal.
View institutional ownership trends.

How do I buy shares of Enliven Therapeutics?

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enliven Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 3/03/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELVN
• CIK: 1672619
• Web: imaratx.com
• Phone: 617-927-9989
• Fax: N/A
• Employees: 50
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Enliven Therapeutics: $43.40
• High Price Target: $56.00
• Low Price Target: $27.00
• Potential Upside/Downside: +4.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$103.69 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.22%
• Return on Assets: -23.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 28.66
• Quick Ratio: 28.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.74 per share
• Price / Book: 5.36

Miscellaneous

• Outstanding Shares: 60,900,000
• Free Float: 45,123,000
• Market Cap: $2.52 billion
• Optionable: Optionable
• Beta: 0.32